摘要
Abstract
Objective To explore the clinical value of stanins combined cardiovascular drug in treatment of coronary heart disease.Methods 110 cases of coronary heart disease in our hospital From Feb. 2013 to Jan. 2016 were selected and randomly divided into observation group and control group with 30 cases of each group. Patients in control group were treated with cardiovascular drug, and patients in observation group were treated with stanins combined cardiovascular drug. After 2 months of treatment, the level of TCH, TG, HDL-C, LDL-C, and clinical effect of the two groups before and after treatment were compared.Results There was no significant difference on efficiency and effective rate of the two groups before and after treatment (P>0.05). But the total effective rate in observation group was higher than control group, and the difference was significant (96.36% vs. 74.55%,P<0.05). After treatment, the level of TCH, TG, HDL-C, LDL-C in the two groups were improved significantly (P<0.05). But the improved condition in observation group was higher than that in control group, and the difference was significant (P<0.05).Conclusion Stanins combined cardiovascular drug in treatment of coronary heart disease can increase the clinical curative effects, and improve the level of TCH, TG, HDL-C, and LDL-C. It was worthy to be clinically popularized and applied.关键词
冠心病/心血管药物/辛伐他汀Key words
Coronary heart disease/Cardiovascular drug/Simvastatin分类
医药卫生
